Trump’s address felt like a rhetorical version of the first few weeks of his administration: a sheer onslaught of executive actions and promises for the future ...

A phase 1/2 trial is evaluating HLD-0915, a novel oral therapy, for metastatic castration-resistant prostate cancer in up to ...